Home / Health / SA TB Research Faces Funding Cuts
SA TB Research Faces Funding Cuts
6 Jan
Summary
- TB remains the deadliest infectious disease globally, killing over 1.2 million in 2024.
- South Africa leads in sophisticated TB research crucial for treatment innovations.
- US funding cuts since early 2025 threaten vital tuberculosis research efforts.
Tuberculosis, recognized as humanity's oldest contagious disease, continues to be the world's deadliest infectious ailment, claiming over 1.2 million lives in 2024. While often an afterthought in developed nations, its impact remains severe globally.
South Africa shoulders a significant TB burden but has concurrently developed advanced scientific capabilities dedicated to studying the disease. Clinical trials conducted within the country have been instrumental in driving innovations in TB treatments, vaccines, diagnostics, and prevention strategies, demonstrating a crucial role in the global fight against TB.
However, a substantial portion of the funding for this vital research originates from American institutions. Since early 2025, these funding streams have been significantly reduced due to policy shifts, casting a shadow over the future of TB research and innovation in South Africa and potentially worldwide.
